These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 14965150)

  • 61. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence.
    Solem C; Mody R; Stephens J; Macahilig C; Gao X
    J Am Pharm Assoc (2003); 2014; 54(2):144-53. PubMed ID: 24632930
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Validation--mission completed?
    Sharp J
    J Parenter Sci Technol; 1993; 47(1):2-3. PubMed ID: 8445494
    [No Abstract]   [Full Text] [Related]  

  • 63. Patient package inserts--instructions or intrusions?
    Harvey MW
    Leg Aspects Med Pract; 1978 Aug; 6(8):47-51. PubMed ID: 703481
    [No Abstract]   [Full Text] [Related]  

  • 64. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 65. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2012 Mar; 77(54):16158-63. PubMed ID: 22479732
    [TBL] [Abstract][Full Text] [Related]  

  • 66. FDA aluminum rule poses challenges for industry, pharmacists.
    Young D
    Am J Health Syst Pharm; 2004 Apr; 61(8):742, 744. PubMed ID: 15127953
    [No Abstract]   [Full Text] [Related]  

  • 67. An exploratory study of drug abuse and dependence information in package inserts.
    Phipps LB; Balster RL; Slattum PW; Kirkwood CK
    J Addict Dis; 2007; 26(2):25-34. PubMed ID: 17594995
    [TBL] [Abstract][Full Text] [Related]  

  • 68. FDA proposes that patient package insert program be rescinded.
    Hospitals; 1982 Feb; 56(4):84. PubMed ID: 7054117
    [No Abstract]   [Full Text] [Related]  

  • 69. Assessment of prescribing information for generic drugs manufactured in the Middle East and marketed in Saudi Arabia.
    Gebran N; Al Haidari K
    Ann Saudi Med; 2006; 26(3):192-9. PubMed ID: 16861873
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016).
    Gnanasakthy A; Barrett A; Evans E; D'Alessio D; Romano CD
    Value Health; 2019 Feb; 22(2):203-209. PubMed ID: 30711065
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Current FDA directives for promoting public health.
    Hayes AH
    Am J Hosp Pharm; 1982 Mar; 39(3):427-31. PubMed ID: 7072727
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The Physicians' Desk Reference. Problems and possible improvements.
    Cohen JS; Insel PA
    Arch Intern Med; 1996 Jul; 156(13):1375-80. PubMed ID: 8678706
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The use of drugs for unlabeled indications.
    Erickson SH; Bergman JJ; Schneeweiss R; Cherkin DC
    JAMA; 1980 Apr; 243(15):1543-6. PubMed ID: 7359738
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Drug package inserts--varying information for the same medicines].
    Storflor JG; Pettersen LC; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2013 May; 133(9):955-9. PubMed ID: 23652143
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Drug counterfeiting and counter measures. Study by the Hungarian National Alliance Against Drug Counterfeiting].
    Psychiatr Hung; 2009; 24(3):205-14. PubMed ID: 20017282
    [No Abstract]   [Full Text] [Related]  

  • 77. Legal implications of preparing and dispensing approved drugs for unlabeled indications.
    Podell LB
    Am J Hosp Pharm; 1983 Jan; 40(1):111-3. PubMed ID: 6823981
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Vioxx may go back on sale after scraping past FDA panel.
    Wadman M
    Nature; 2005 Feb; 433(7028):790. PubMed ID: 15729304
    [No Abstract]   [Full Text] [Related]  

  • 79. International Conference on Harmonisation; guidance on good manufacturing practice for active pharmaceutical ingredients; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Sep; 66(186):49028-9. PubMed ID: 12358036
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Patient package inserts: the proper prescription?
    Rowe HM
    Food Drug Law J; 1995; 50(1):95-124. PubMed ID: 10342988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.